CN Survey 1110

Article

Offer Terms: Offer available only to licensed physicians who register as members of CancerNetwork.com prior to November 30, 2010, subject to UBM Medica's verification of member's licensure status. Registrants must be (i) legal residents of the fifty United States (and the District of Columbia), (ii) at least 18 years of age, and (iii) licensed physicians, as of the date of their registration. Employees of UBM Medica, its parent company, affiliates and subsidiaries, and their agents, subcontractors, suppliers, as well as the immediate family (spouse, parents, siblings, and children) and household members of each such employee are not eligible to receive incentive. Limit 1 gift card per person. Offer is not retroactive to previously registered members. The gift card code will be e-mailed to you within 7 - 10 business days of November 30, 2010 at the e-mail address on file with UBM Medica (in user’s member profile). E-mail address on file must be a valid, working e-mail address in order to receive incentive.  

 

Thank you for registering to CancerNetwork.com. 

 

Click here to participate in the survey

Offer Terms: Offer available only to licensed physicians who register as members of CancerNetwork.com prior to November 30, 2010, subject to UBM Medica's verification of member's licensure status. Registrants must be (i) legal residents of the fifty United States (and the District of Columbia), (ii) at least 18 years of age, and (iii) licensed physicians, as of the date of their registration. Employees of UBM Medica, its parent company, affiliates and subsidiaries, and their agents, subcontractors, suppliers, as well as the immediate family (spouse, parents, siblings, and children) and household members of each such employee are not eligible to receive incentive. Limit 1 gift card per person. Offer is not retroactive to previously registered members. The gift card code will be e-mailed to you within 7 - 10 business days of November 30, 2010 at the e-mail address on file with UBM Medica (in user’s member profile). E-mail address on file must be a valid, working e-mail address in order to receive incentive.
 

 

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content